

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

N. M. Archin¹, A. L. Liberty¹, A. D. Kashuba¹, S. K. Choudhary¹, J. D. Kuruc¹, A. M. Crooks¹, D. C. Parker¹, E. M. Anderson², M. F. Kearney², M. C. Strain³, D. D. Richman³, M. G. Hudgens¹, R. J. Bosch⁴, J. M. Coffin², J. J. Eron¹, D. J. Hazuda⁵ & D. M. Margolis¹

Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection¹. Inducing the expression of latent genomes within resting CD4⁺ T cells is the primary strategy to clear this reservoir^{2,3}. Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency *in vitro*^{4–6}, the utility of this approach has never been directly proven in a translational clinical study of HIV-infected patients. Here we isolated the circulating resting CD4⁺ T cells of patients in whom viraemia was fully suppressed by antiretroviral therapy, and directly studied the effect of VOR on this latent reservoir. In each of eight patients, a single dose of VOR increased both biomarkers of cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting CD4⁺ cells (mean increase, 4.8-fold). This demonstrates that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.

Among the many important aims of future HIV research is the development of therapies of finite duration capable of eradicating HIV infection. The persistence of quiescent HIV infection within a small population of long-lived CD4⁺ T cells is currently a major obstacle to this goal¹. Histone deacetylases (HDACs) are recruited to the HIV long terminal repeat (LTR) promoter, establishing one of several restrictions that can limit LTR expression and maintain viral latency^{2,3}. Deacetylated LTR chromatin seems to play a key contributory role in regulating HIV expression, and especially in maintaining proviral quiescence and latency. *In vitro*, HDAC inhibitors have been shown to disrupt latent proviral HIV infection in both cell culture models and *ex vivo* assays using cells from HIV-1-infected patients. Although disrupting latency has been proposed as part of a strategy to eradicate HIV infection, previous studies using the weak HDAC inhibitor valproic acid did not consistently demonstrate a marked depletion of resting cell infection^{7–11} in patients on antiretroviral therapy (ART). However, the effects measured in these studies are significantly downstream of the molecular site of action of HDAC inhibitors, and thus the proximal pharmacodynamic measures of HDAC inhibitor activity and HIV-1 expression were not evaluated. Here we show that HDAC inhibitors disrupt the latency of proviral genomes within resting CD4⁺ T cells, establishing the first (to our knowledge) class of drugs that could lead to the eradication of HIV infection.

VOR is a potent HDAC inhibitor used to treat human malignancies. At clinically relevant concentrations, VOR inhibits the class I HDACs most important for repression of HIV expression^{4,12}; it also induces LTR expression and virus production *in vitro* from the resting CD4⁺ T cells of HIV-positive patients on ART with levels of plasma HIV RNA below the detection limit (BDL)^{5,6,13}. As the most proximal measure of

effect on latent infection is expression of HIV-1 RNA, we developed a sensitive assay to enable a direct measurement of unspliced *gag* HIV RNA within the resting CD4⁺ T cells of HIV-infected patients. The assay has a limit of detection of 1 copy per million resting CD4⁺ T cells, and a limit of quantification of 10 copies per million resting CD4⁺ T cells.

To evaluate the effect of VOR on latent infection *in vivo*, HIV-infected patients receiving stable ART with plasma HIV-1 RNA <50 copies per ml for at least 6 months and a CD4 count >300 μl^{-1} were enrolled following informed consent. To demonstrate that it was ethical to expose patients to an experimental agent with potential risk in a study with no proven clinical benefit for the individual, we validated the ability of this assay of HIV RNA within resting CD4⁺ T cells to measure HIV expression at baseline, and to detect up-regulation of HIV expression in resting cells from each patient after physiological exposure to VOR.

Patients maintained suppressive ART, and purified populations of resting CD4⁺ T cells were obtained by continuous-flow leukapheresis and negative selection in an immunomagnetic column⁷. To establish a baseline, we measured the mean quantity of HIV-1 *gag* RNA in pools of 1 million resting CD4⁺ T cells immediately after their isolation from patients. To measure validated biomarkers of VOR effect in peripheral blood mononuclear cells (PBMCs) of patients, we performed parallel assays of total cellular histone acetylation and measured histone acetylation by chromatin immunoprecipitation (ChIP) at the human p21 gene promoter, a gene known to upregulate chromatin acetylation after VOR exposure¹⁴. Then to model the effect of a clinical dose of VOR, multiple replicate pools of 1 million resting CD4⁺ T cells were incubated in complete media alone, with 335 nM VOR, or with 3 μg phytohaemagglutinin (PHA) and 60 U interleukin-2 (IL-2) for 6 h. VOR conditions were selected to mimic the unbound drug exposure expected after a single 400 mg dose of VOR *in vivo*⁵.

Validation assays were performed in resting CD4⁺ T cells isolated by leukapheresis from 16 patients with plasma HIV RNA BDL (Fig. 1a). In each patient a total of 48–72 million highly purified resting CD4⁺ T cells were studied; that is, 12–48 million cells in each condition, depending on cell availability. In 9 patients following 6 h of culture of 16–24 million cells without stimulation in media alone, HIV *gag* RNA was quantifiable at a mean level of 52 ± 32 copies per million cells. However, in the other 7 patients in whom 12–24 million cells were studied (Fig. 1a), HIV RNA was not quantifiable at a limit of 10 copies per million cells, although in all but 2 of these patients RNA was detected but not quantifiable (>0 but <10 copies per million cells).

Following *in vitro* exposure to 335 nM VOR for 6 h, HIV RNA expression was significantly upregulated in 8 of 9 patients in whom resting CD4⁺ T cell HIV RNA was quantifiable without HDAC inhibitor exposure, and also in 3 of 7 patients in whom cell-associated HIV RNA was <10 copies per million cells before HDAC inhibitor exposure. In

¹The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. ²HIV Drug Resistance Program, NCI, NIH, Frederick, Maryland 21702, USA. ³VA San Diego Healthcare System and University of California San Diego, San Diego, California 92093, USA. ⁴Harvard School of Public Health, Boston, Massachusetts 02115, USA. ⁵Merck Research Laboratories, White Horse Junction, Pennsylvania 08889, USA.




Figure 1 | The relative HIV-1 RNA copy number in resting CD4⁺ T cells of 16 ART-treated HIV-positive patients with plasma HIV RNA BDL. Values are calculated by cycle number, and the limit of quantification of cell-associated RNA is 10 copies. Cells were cultured alone (untreated), with VOR 335 nM ('*ex vivo* VOR'), or activated with 3 $\mu\text{g ml}^{-1}$ PHA and 60 U ml^{-1} IL-2 for 6 h ('*ex vivo* PHA'). **a**, Data from 16 patients; **b**, data from eight of those patients (Pt 1–8) who later received *in vivo* dosing (mean and s.d.). The patients in **b** are identified by the following symbols in **a**: patient 1, upright open triangle; 2, open square; 3, open diamond; 4, cross; 5, inverted open triangle; 6, open circle; 7, 'plus' sign; 8, open dotted circle.

all 11 patients in whom expression was induced by VOR, HIV RNA expression was also induced after 6 h of exposure to PHA. Levels of HIV RNA induction were similar after 6 h of exposure to PHA or VOR, although in other experiments (data not shown) levels of HIV RNA plateaued after 6 h of exposure to VOR, but continued to increase when PHA exposure was extended for up to 16 h.

Of the 11 eligible patients in whom an induction of HIV RNA expression following *in vitro* exposure to VOR could be measured, eight patients (Fig. 1b; CD4 count 432–1,147 μl^{-1} , mean 713 μl^{-1}) continued their long-term ART (tenofovir, emtricitabine and efavirenz in all) and agreed to receive a single dose of VOR at 200 mg to ascertain tolerability. Global cellular histone acetylation in PBMCs was unchanged up to 24 h after dosing, and histone acetylation at the human p21 gene promoter was modestly increased in only two patients (data not shown).

Two to four weeks later the safety and tolerability of a 400 mg dose of VOR was assessed, including acetylation measurements, and VOR plasma concentrations measured serially up to 24 h after dosing (Fig. 2). Maximum VOR concentrations of 244 ng ml^{-1} (median, range 153–301) occurred a median of two hours (range 0.5–4) after dosing. VOR pharmacokinetics were similar to those reported in other

populations^{15,16}. This exposure resulted in a significant increase ($P < 0.01$) in acetylation of total cellular histone H3 (median 1.6-fold) in all eight patients, and trend towards increased acetylation of histones at the human p21 gene as measured by ChIP in patients 2, 3, 4, 5, and 7 for whom sufficient cells were available (Fig. 2).

Four to five weeks later, a second dose of 400 mg of VOR was administered and resting CD4⁺ T cells collected 4–7 h later, after the previously measured peak VOR level. We measured HIV RNA in multiple pools of resting CD4⁺ T cells within this window of time, when cellular biomarkers of increased acetylation had been previously documented, and induction of HIV LTR expression mediated by HDAC inhibitor activity would be possible. During exposure to VOR, an increase of 1.5- to 10.0-fold (mean 4.8) in expression of unspliced HIV-1 gag RNA within resting CD4⁺ T cells was measured in all eight patients (Fig. 3). Expression following the 400 mg dose was significantly increased ($P < 0.01$) when compared to baseline levels of RNA expression for all patients. Patients 1 and 2 underwent leukapheresis 3 to 4 months after dosing and protocol completion to provide cells for other research, and in both cases a statistically significant decline in HIV RNA expression per million resting CD4⁺ T cells after VOR dosing was observed (patient 1: after VOR




Figure 2 | VOR exposure and histone acetylation. Median VOR plasma concentrations in patients 1–8 after a single 400 mg oral dose (open circles; error bars show range) are shown in comparison with mean fluorescence intensity (MFI) of total cellular acetylated histone H3 in PBMCs (filled diamonds; error bars show ± 1 s.d.), and relative levels of acetylated histone H3

at the human p21 gene promoter in resting CD4⁺ T cells (histogram; data show mean ± 1 s.d.). A significant increase ($P < 0.01$) in cellular acetylated histone H3 is seen at 8 h. A trend towards increased acetylation at the p21 gene is seen in the patients (2–5, 7) in whom sufficient cells were available for analysis.




Figure 3 | VOR upregulates HIV RNA expression. The relative HIV-1 RNA copy number (mean + 1 s.d.) measured in the resting CD4⁺ T cells of eight HIV-positive patients with plasma HIV RNA BDL is shown on background ART and on ART following a single 400 mg oral dose of VOR. For each subject, the differences are significant ($P < 0.01$).

290 copies, off-protocol 70 copies per million cells, $P < 0.001$; patient 2: after VOR 186 copies, off-protocol 105 copies per million cells, $P = 0.003$). These observations support the conclusion that the increase in HIV RNA expression was causally related to VOR exposure. This conclusion assumes that the isolation of RNA from resting CD4⁺ T cells largely excludes actively infected cells, and reflects RNA expression in cells that are functionally defined as latently infected¹⁷.

Throughout this limited exposure, VOR was well tolerated, with no adverse events greater than grade I; none of these effects were attributable to VOR. Additionally, we measured single-copy assay viraemia¹⁸ on occasions before VOR exposure, and at 8 and 24 h after doses of 200, 400 and 400 mg of VOR (10 assays in total). Despite the upregulation of HIV RNA expression measured in circulating resting CD4⁺ T cells, no significant change of low-level viraemia was observed. Median plasma HIV RNA (in copies per ml) by single-copy assay in these 8 patients was 13 (range 3 to 23), <1.0 (range <1 to 3), 2 (range <1 to 3), <1 (range <1 to 1), 3 (range 1 to 6), <1 (range <1 to 5), <1 (range <1 to 1.2), and <1 in all assays, with no consistent trend towards an increase in plasma HIV RNA after VOR exposure.

This study demonstrates that the quiescence of latent, integrated HIV provirus within resting CD4⁺ T cells, a significant barrier to the eradication of HIV infection, can be disrupted by an achievable and tolerable exposure to an HDAC inhibitor. A single, clinically tolerable dose of VOR induces the expected biological effect—histone acetylation—consistent with HDAC inhibitor exposure within the PBMCs of HIV-infected, ART-treated patients. These effects are temporally associated with increased levels of HIV RNA expression detected within resting CD4⁺ T cells, demonstrating that, at least for a period of time in some infected cells, all of the restrictions that limit the expression of latent proviral genomes have been overcome. Nevertheless, although histone deacetylation is associated with HIV RNA expression, the precise molecular mechanisms through which VOR mediates this effect remain to be fully explained.

HIV RNA induction *in vivo* often appeared to be of greater magnitude than that seen *in vitro*, perhaps due to an underestimation in the modelling of physiological exposure *in vitro*, or other phenomena induced by drug exposure *in vivo*. Further testing will be required to determine if the *in vitro* assay presented here is predictive of a subset of patients who do not respond to VOR, or if such pre-screening is unnecessary. Nevertheless, assays of HIV RNA associated with resting CD4⁺ T cells may be useful in the pre-clinical and clinical testing of new and combination approaches to disrupt HIV latency.

Precise studies will be required to determine which dosing regimens of VOR or other HDAC inhibitors are safe and result in sustained

disruption of HIV latency. We did not observe an alteration of low-level viraemia. This may be due to the very low levels of plasma viraemia present in these patients at baseline, that our sampling missed the brief effect of a single exposure to VOR, or that stable, low-level viraemia reflects virion production from sources other than resting CD4⁺ T cells. Further, a limited evaluation did not reveal a substantial reduction in the frequency of replication-competent HIV within resting CD4⁺ T cells (data not shown). This is not surprising, as such an effect is likely to require more than a single dose of VOR, or additional interventions to clear infected cells. These are important goals for future studies.

VOR, like the HDAC inhibitor in wide clinical use, valproic acid, is deemed a mutagen as predicted by the Ames test in bacteria, although DNA damage induced by VOR is known to be repaired in normal human cells^{19,20}. Mutations in normal cells are not observed following long-term growth in the presence of VOR (P. A. Marks, personal communication). Nevertheless, the risks and benefits of attempts to eradicate HIV infection will have to be carefully weighed. Whereas it remains to be seen if the use of VOR in combination with suppressive ART is sufficient to result in the depletion of latently infected resting CD4⁺ T cells, or whether additional interventions are required, these findings demonstrate that therapy targeted at persistent, latent infection within resting CD4⁺ T cells is feasible, and open the way for the development of HDAC inhibitors with improved specificity, potency and safety profiles for the selective targeting of latent proviral genomes.

METHODS SUMMARY

HIV-infected patients receiving stable, standard-of-care ART with plasma HIV-1 RNA <50 copies per ml and a CD4 count of >300 μl^{-1} for at least 6 months were enrolled following informed consent. Studies were approved by the UNC institutional biomedical review board and the Food and Drug Administration.

Leukapheresis was performed and resting CD4⁺ T cells isolated⁸. *Ex vivo* HIV-1 RNA production in resting CD4⁺ T cells was measured following incubation in media containing 335 nM VOR, or 3 $\mu\text{g ml}^{-1}$ PHA and 60 U ml^{-1} IL-2, or media alone for 6 h. To provide a baseline for the *in vivo* response to VOR, other resting CD4⁺ T cells were immediately frozen and stored.

Total RNA was isolated from 12 to 48 pools of 1 million resting cells, duplicate pools of cDNA were synthesized, and duplicate PCR amplification performed²¹. A standard curve was generated for each PCR reaction from *in vitro* transcribed RNA²². Results of the four PCR replicates representing each of the original 12 to 48 pools of RNA were averaged and the standard deviation determined for each condition. The Wilcoxon rank sum test was used to calculate the statistical significance of all comparisons between conditions.

To measure total histone acetylation, PBMCs were fixed, permeabilized and stained with anti-acetyl histone H3 and a FITC-conjugated secondary antibody, and analysed by flow cytometry. ChIP was performed as previously⁴ but 1×10^6 sonicated PBMCs were used for immunoprecipitation with anti-acetyl-histone H3 or pre-immune globulin, and PCR of performed using primers targeting the human p21 promoter²³.

Pharmacokinetic assays of VOR were performed before dosing and at 0.25, 0.50, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 and 24 h after dosing. VOR was measured using a modification of the method of ref. 15.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

Received 13 February; accepted 7 June 2012.

- Blankson, J. N., Persaud, D. & Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. *Annu. Rev. Med.* **53**, 557–593 (2002).
- Margolis, D. M. Histone deacetylase inhibitors and HIV latency. *Curr. Opin. HIV AIDS* **6**, 25–29 (2011).
- Van Lint, C. *et al.* Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. *EMBO J.* **15**, 1112–1120 (1996).
- Archin, N. M. *et al.* Expression of latent human immunodeficiency type-1 is induced by novel and selective histone deacetylase inhibitors. *AIDS* **23**, 1799–1806 (2009).
- Archin, N. M. *et al.* Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. *AIDS Res. Hum. Retroviruses* **25**, 207–212 (2009).
- Contreras, X. *et al.* Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. *J. Biol. Chem.* **284**, 6782–6789 (2009).

7. Lehrman, G. *et al.* Depletion of latent HIV infection *in vivo*: a proof of concept study. *Lancet* **366**, 549–555 (2005).
8. Archin, N. M. *et al.* Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4⁺ T cells. *AIDS* **22**, 1131–1135 (2008).
9. Siliciano, J. D. *et al.* Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. *J. Infect. Dis.* **195**, 833–836 (2007).
10. Sagot-Lerolle, N. *et al.* Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS* **22**, 1125–1129 (2008).
11. Archin, N. M. *et al.* Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4⁺ cell infection. *PLoS ONE* **5**, e9390 (2010).
12. Keedy, K. S. *et al.* A limited group of class I histone deacetylases act to repress human immunodeficiency virus type-1 expression. *J. Virol.* **83**, 4749–4756 (2009).
13. Edelstein, L. C., Micheva-Viteva, S., Phelan, B. D. & Dougherty, J. P. Activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. *AIDS Res. Hum. Retroviruses* **25**, 883–887 (2009).
14. Gui, C. Y. *et al.* Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. *Proc. Natl Acad. Sci. USA* **101**, 1241–1246 (2004).
15. Du, L., Musson, D. G. & Wang, A. Q. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. *Rapid Commun. Mass Spectrom.* **19**, 1779–1787 (2005).
16. Rubin, E. H. *et al.* A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. *Clin. Cancer Res.* **12**, 7039–7045 (2006).
17. Hermankova, M. *et al.* Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4⁺ T lymphocytes *in vivo*. *J. Virol.* **77**, 7383–7392 (2003).
18. Palmer, S. *et al.* New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. *J. Clin. Microbiol.* **41**, 4531–4536 (2003).
19. Lee, J. H., Choy, M. L., Ngo, L., Foster, S. S. & Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. *Proc. Natl Acad. Sci. USA* **107**, 14639–14644 (2010).
20. Lee, J. H., Choy, M. L., Ngo, L., Venta-Perez, G. & Marks, P. A. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. *Proc. Natl Acad. Sci. USA* **108**, 19629–19634 (2011).
21. Israel-Ballard, K. *et al.* TaqMan RT-PCR and VERSANT HIV-1 RNA 3.0 (bDNA) assay quantification of HIV-1 RNA viral load in breast milk. *J. Clin. Virol.* **34**, 253–256 (2005).
22. Robinson, L. H., Gale, C. V. & Kleim, J. P. Inclusion of full-length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping. *J. Virol. Methods* **104**, 147–160 (2002).
23. Radonić, A. *et al.* Guideline to reference gene selection for quantitative real-time PCR. *Biochem. Biophys. Res. Commun.* **313**, 856–862 (2004).

Acknowledgements This study was supported by National Institutes of Health grants AI084553, AI095052 and AI096113, and by a grant from Merck & Co to D.M.M., National Institutes of Health grants RR024383 to the UNC TRACS Institute, AI50410 to the UNC Center for AIDS Research, and an equipment grant from the James B. Pendleton Charitable Trust. Merck & Co provided VOR. The ClinicalTrials.gov identifier is NCT01319383. We thank N. P. Dahl, R. Sackmann, M. Cheema, A. Wiegand and N. White for technical support, Y. Park and the staff the UNC Blood Bank, R. J. Bedimo and C. M. van der Horst for study oversight, and J. Scepanski and A. Sugarbaker for patient follow-up and study coordination. We thank M. S. Cohen, J. V. Garcia-Martinez, W. C. Greene, J. Karn and R. F. Siliciano for discussions. Finally, we are grateful for the contributions of the patients who have participated in these studies.

Author Contributions N.M.A., A.L.L., D.C.P., S.K.C., M.C.S., D.D.R., D.J.H. and D.M.M. designed and performed primary study assays and performed study analysis. J.D.K., A.M.C., J.J.E. and D.M.M. designed, implemented and oversaw the clinical protocol. M.G.H. and R.J.B. designed the data analysis. A.D.K. oversaw pharmacokinetic assays and analysed these data. M.F.K., E.M.A. and J.M.C. designed and performed single-copy assays.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests; details accompany the full-text HTML version of the paper at www.nature.com/nature. Readers are welcome to comment on the online version of this article at www.nature.com/nature. Correspondence and requests for materials should be addressed to D.M.M. (dmargo@med.unc.edu).

METHODS

Patients/study procedures. HIV-infected patients receiving stable, standard-of-care ART with plasma HIV-1 RNA <50 copies per ml and a CD4 count of >300 μl^{-1} for at least 6 months were enrolled following informed consent. Studies were approved by the UNC institutional biomedical review board and the Food and Drug Administration. Leukapheresis was performed and *ex vivo* VOR response assayed. Patients with *ex vivo* VOR response were then administered a 200 mg dose of VOR (donated by Merck Research Laboratories) to assess safety and tolerability, followed by a 400 mg dose four or more weeks later during which pharmacokinetic parameters, including maximum concentration (C_{max}) and apparent oral clearance (CL/F), as well as levels of global cellular histone and human p21 promoter histone H3 acetylation. A second 400 mg dose of VOR was administered four or more weeks later, and apheresis spanning the time point of measured C_{max} VOR concentrations was performed to assay *in vivo* VOR response.

Measurement of resting CD4⁺ T-cell-associated HIV-1 RNA. Leukapheresis and isolation of resting CD4⁺ T cells have been described elsewhere⁴. To measure the *ex vivo* response of resting CD4⁺ T cells to VOR, cells were incubated in media containing 335 nM VOR (Merck Research Laboratories) or 3 $\mu\text{g ml}^{-1}$ PHA (Remel) and 60 U ml^{-1} IL-2 or media alone for 6 h. Cells were washed and plated at 10^6 per well in a 96-well plate and pelleted. Cell pellets were snap frozen and stored at -80°C . To measure the *in vivo* response to VOR, immediately following leukapheresis, resting CD4⁺ T cells were isolated and plated at 10^6 cells per well, pelleted, snap frozen, and stored at -80°C .

Total RNA was isolated from 12 to 48 pools of 10^6 resting cells using the Magmax 96 Total RNA isolation kit (Ambion) following the manufacturer's protocol. Duplicate pools of cDNA were synthesized from DNase-treated, isolated RNA using the SuperScript III First-Strand Synthesis SuperMix kit (Invitrogen) according to the manufacturer's procedures. Two additional duplicate wells from each treatment condition did not include reverse transcriptase and served as control for DNA contamination. Duplicate PCR amplification of duplicate cDNA was performed using the ABI7500 Fast Real-Time PCR machine and previously published primers and probe. A standard curve was generated for each PCR reaction using cDNA synthesized from *in vitro* transcribed RNA where the p5' plasmid served as template²². Results of the four PCR replicates representing each of the original 12 to 48 pools of RNA were averaged and the standard deviation determined for each condition. Inputs for samples in which basal and VOR-induced HIV RNA expression were measured (Fig. 3) were compared by the quantification of TATA binding protein RNA²³ and the quantification of total HIV DNA, and showed no trend towards higher values in the post-VOR samples.

We determined that our HIV RNA PCR assay could detect the difference between 1 copy and ≥ 10 copies using dilutions of an HIV RNA internal standard²⁴. Detectable PCR signal less than 10 copies (1–9 copies) was treated in all analyses as 5 copies. No PCR signal or <1 copy was treated in all analyses as 0 copies. As the entire pool of cDNA was not amplified, and individual PCR amplifications are therefore subject to stochastic sampling effects, we have termed the

result 'relative HIV-1 *gag* RNA copies'. The Wilcoxon rank sum test was used to calculate the statistical significance of all comparisons between conditions.

Measurement of total histone acetylation by flow cytometry. PBMCs collected before and after 400 mg VOR dosing were fixed and permeabilized using Phosflow fix buffer I and Phosflow permeabilization buffer II (BD Biosciences) according to the manufacturer's protocol. Cells were then washed in stain buffer (2% FBS, 0.09% sodium azide), blocked with 8% normal goat serum (Invitrogen), and incubated with anti-acetyl histone H3 (1:100 dilution, catalogue no. 06-599, Millipore) or control rabbit IgG, in blocking solution for 60 min at room temperature. Cells were then washed and incubated with goat-anti-rabbit IgG FITC conjugated secondary antibody (1:250 dilution, Millipore) in stain buffer for 30 min at 25°C in the dark. Following a final wash, cells were analysed by flow cytometry using a CyAn ADP flow cytometer and Summit 4.3 software (Beckman Coulter).

Chromatin immunoprecipitation (ChIP). ChIP assays were performed as previously described⁹ with the following modifications: PBMCs were cross-linked with 1% formaldehyde and nuclei extracted using the appropriate buffers (Diagenode). Nuclei were lysed using an SDS lysis buffer containing mammalian protease cocktail inhibitor (Sigma) and sonicated to fragment chromatin to 500–1,000 base pairs using a Bioruptor standard sonicator (Diagenode). 1×10^6 sonicated cells were used to set up each immunoprecipitation reaction using 5 μg of anti-acetyl-histone H3 (Ac-H3, catalogue no. 17-615, Millipore) or rabbit pre-immune immunoglobulin G (Sigma). PCR of immunoprecipitates or input DNA was performed using primers targeting the human p21 promoter²⁵. The percent of immunoprecipitated p21 promoter DNA was determined by comparing the cycle threshold values of each reaction to a standard curve generated from input DNA and is reported as the percent of input.

Measurement of VOR pharmacokinetics. Five millilitres of blood were collected without anticoagulant for pharmacokinetic assays before dose and at 0.25, 0.50, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 and 24 h after dosing. Blood samples were allowed to clot at room temperature for 30 min, centrifuged at 2,000g for 15 min at 4°C , and stored at -70°C until analysis. VOR concentrations were measured from human serum using a modification of the method of ref. 14. Individual serum concentrations were used to estimate VOR pharmacokinetic variables $\text{AUC}_{0-24\text{h}}$, C_{max} , T_{max} , CL/F and apparent terminal $t_{1/2}$. WinNonlin Phoenix was used for the calculations. The apparent terminal $t_{1/2}$ was estimated from the best-fit variables of a single exponential to the log-linear portion of the serum concentration versus time curve using unweighted linear regression. $\text{AUC}_{0-24\text{h}}$ was calculated using the linear up/log down method. C_{max} and T_{max} were obtained by inspection of the concentration–time data.

24. May, R. C. *et al.* Change-Point Models to Estimate the Limit of Detection (Working Paper 26, University of North Carolina at Chapel Hill Biostatistics Technical Report Series, March 2012); available at <http://biostats.bepress.com/uncbiostat/papers/art26>.
25. Tonelli, R. *et al.* G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. *Leukemia* **20**, 1307–1310 (2006).

ERRATUM

doi:10.1038/nature11455

Erratum: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

N. M. Archin, A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, A. M. Crooks, D. C. Parker, E. M. Anderson, M. F. Kearney, M. C. Strain, D. D. Richman, M. G. Hudgens, R. J. Bosch, J. M. Coffin, J. J. Eron, D. J. Hazuda & D. M. Margolis

Nature **487**, 482–485 (2012); doi:10.1038/nature11286

In the print and PDF versions of this Letter, the statement at the end of the paper that there was Supplementary Information linked to the online version of the paper was incorrect; this statement has now been removed in the PDF version of the manuscript.